 WALTHAM, Mass., Sept. 21, 2021 GLOBE NEWSWIRE -- Viridian Therapeutics, Inc. NASDAQ: VRDN, a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by todays therapies, today announced the pricing of an underwritten public offering with gross proceeds of approximately 85.0 million. Viridian is selling a total of 6,185,454 shares of common stock at a public offering price of 11.00 per share and 23,126 shares of series B preferred stock the Series B Preferred at a public offering price of 733.37 per share, which are convertible into approximately 1,541,810 shares of common stock, subject to beneficial ownership conversion limits. In addition, Viridian has granted the underwriters a 30-day option to purchase an additional 1,159,089 shares of common stock at the public offering price less underwriting discounts and commissions. All of the shares to be sold in the underwritten public offering are being offered by Viridian. The offering is expected to close on or about September 23, 2021, subject to customary closing conditions. 